Headache, Migraine
Conditions
Brief summary
To investigate headache score and accompanying symptoms during and after infusion of the natriuretic peptides.
Interventions
DRUGNatriuretic peptides
I.V. infusion between 0.2-3 microgram over 20 minutes
Sponsors
Danish Headache Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers * Aged 18-40 * 50-100 kg * Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen.
Exclusion criteria
* Tension type headache more than once/month * Other primary headaches * Daily medication except contraceptives * Drug taken within 4 times the halflife for the specific drug except contraceptives * Pregnant or lactating women * Exposure to radiation within the last year * Headache within the last 24 hours before start of trial * Hypertension * Hypotension * Respiratory or cardiac disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Headache intensity, mean velocity of blood flow in the middle cerebral artery (VmeanMCA), superfical temporal artery diameter, PetCO2, adverse events and vital signs were recorded at T-10, T0 and then every 10 min until 120 min after start of infusion. | Every 10 min. |
Secondary
| Measure | Time frame |
|---|---|
| All subjects were asked to complete a headache diary every hour until 10 h after the discharge. The diary included headache characteristics and accompanying symptoms according to the International Headache Society (IHS 2004) | 10 hours after discharge |
Countries
Denmark
Outcome results
None listed